Blepharospasm
32
0
0
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
2 terminated out of 32 trials
91.7%
+5.2% vs benchmark
13%
4 trials in Phase 3/4
18%
4 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (32)
DaxibotulinumtoxinA for Blepharospasm
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Blepharospasm Patient Survey for Patients With Blepharospasm
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
An RCT of a Patient-initiated Treatment Service for BEB and HFS
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
Post Marketing Surveillance Study of Dysport
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
Blepharospasm Tools
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions
A Mechanical Device for Blepharospasm
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
Brain Changes in Blepharospasm